- 1.2.5Tsai CF, Tu PC, Wang YP, Chu CJ, Huang YH*, Lin HC, Hou MC, Lee FY, Liu PY, Lu CL*. Altered cognitive control network is related to psychometric and biochemical profiles in covert hepatic encephalopathy. Sci Rep. 2019; 9:6580 | https://doi.org/10.1038/s41598-019-42957-6 (IF: 4.011)
- 1.2.5Chen WC, Hsin IF, Chen PH, Hsu PI, Wang YP, Cheng JS, Lin HS, Hou MC*, Lee FY. Addition of Carvedilol to Gastric Variceal Obturation Does Not Decrease Recurrence of Gastric Variceal Bleeding in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2019 Feb 14 (IF: 7.958)
- 1.2.5Kao WY, Su CW*, Chia-Hui Tan E, Lee PC, Chen PH, Tang JH, Huang YH, Huo TI, Chang CC, Hou MC, Lin HC, Wu JC. Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C. Hepatology. 2019 Mar (IF: 14.971)
- 1.2.Chen CY, Wang YP, Lu CL*. An Unusual Hepatic Mass in a Young Man. Gastroenterology 2019;157:E4-E5. (IF:19.809)
- 1.2.4Chen YJ, Tsai CF, Wang YP, Lu CL*. Letter to the Editor: Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis. Hepatology 2019;70:760-761. (IF:14.971)
- 1.2.4Chang CC, Chuang CL, Tsai MH, Hsin IF, Hsu SJ, Huang HC*, Lee FY, Lee SD.Effects of Caffeine Treatment on Hepatopulmonary Syndrome in Biliary Cirrhotic Rats.Int J Mol Sci. 2019 Mar 28 (IF: 4.183)
- 1.2.4Chang CC, Lee WS, Chuang CL, Hsin IF, Hsu SJ, Huang HC*, Lee FY, Lee SD.Effect of ivabradine, a funny current inhibitor, on portal hypertensive rats. J Chin Med Assoc. 2019 Jan (IF: 1.894)
- 1.2. Wang YP ,Liu YW, Yen SF, Liu PY, Tzeng WJ, Tsai CF, Lin HC, Lee FY, Jeng JO, Lu CL* Tsai YC*. Lactobacillus plantarum PS128 Ameliorated Visceral Hypersensitivity in Rats Through the Gut–Brain Axis. Probiotics and Antimicrobial protein. 2019 in press (IF: 2.962)
- 1.2.Wang YP, Herndon CC, Lu1 CL*. Non-pharmacological Approach in the Management of Funcioanl Dyspepsia. J Neurogastroenterol Motil 2019 in press (IF: 3.179)
- 1.2.5Herdon CC, Wang YP, Lu CL*. Targeting the gut microbiota for the treatment of irritable bowel syndrome. Kaoshung J Med Sci 2019 in press (IF: 1.291)
Last Modified：